A real world study to evaluate the efficacy and treatment adherence of Apalutamide in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC)
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Apalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 17 Sep 2021 New trial record
- 11 Sep 2021 Results presented in a Janssen Pharmaceuticals media release.